It is stated that the application for the patent was filed in March but it was approved only now. The patent is issued by the National Intellectual Property Administration.
It is noted that the research in the first two stages showed the efficiency and safety of the sample. The last stage will take place in the form of mass testing. The duration of protection, the safe dose for different categories of people will be determined at the last stage of testing of the vaccine.
The vaccine contains the genetic material of the coronavirus. The drug should force the organism of a human to produce antibodies that are able to detect spike protein of coronavirus and fight it.
On August 11, President of Russia Vladimir Putin reported that the first vaccine against coronavirus was registered in Russia.
It is noted that the vaccine would be produced by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology and Russian Binnopharm Company. According to Murashko, finalizing takes place of the technical regulations for scaling of production at the number of Russian productions.